Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 7, 2018

Primary Completion Date

March 31, 2022

Study Completion Date

September 15, 2022

Conditions
Non-small Cell Lung Cancer Stage IV
Interventions
DRUG

Atezolizumab

"* Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."

Trial Locations (15)

15006

Complejo Hospitalario de la Coruña, A Coruña

17007

Hospital Dr. Josep Trueta, Girona

28040

Hospital Fundación Jiménez Díaz, Madrid

36036

Complexo Hospitalario Universitario de Vigo, Vigo

46014

Hospital General Universitario de Valencia, Valencia

46026

Hospital La Fe, Valencia

47003

Hospital Clínico Universitario de Valladolid, Valladolid

03203

Hospital General Universitario de Elche, Elche

08916

Hospital Universitari Germans Tries i Pujol, Badalona

08908

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

Unknown

Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria

H. La Paz, Madrid

03010

Hospital General de Alicante, Alicante

08035

H.U.Vall D´Hebrón, Barcelona

08041

Hospital de Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
lead

Spanish Lung Cancer Group

OTHER

NCT03526900 - Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis | Biotech Hunter | Biotech Hunter